Locally Advanced Rectal Cancer: A Quoted Percentage Is Not the Group Survival Rate

Short answer

A quoted shift from 30 to 90 percent is one conversation, not a group rate. Dutch stage I to III rectal cancer had 5-year relative survival near 80 to 85 percent, not stage IV. A high-risk trial still showed 23.7 percent treatment failure at 3 years in the stronger arm.

What was shared in the group

One member described rectal cancer written as stage 3 to 4 with several lymph nodes, a percentage once heard in the 30 to 40 range, and a higher percentage heard years later, along with self-care and morale. Another person described cancers in different organs. This page names no one. One recounted percentage is not the next person’s survival.

If CEA has returned to the reference range, read CEA after stage 3–4 colorectal cancer. For morale beside hospital treatment, read morale does not replace cancer treatment. For neoadjuvant treatment and a stoma, read neoadjuvant therapy for rectal cancer.

1. Nodes in the pelvis are not the same group as distant organ spread

A Dutch registry of 25,995 people with stage I to III rectal cancer diagnosed from 2015 to 2023 found 5-year relative survival of about 79.5 percent in the lower socioeconomic group, 82.4 percent in the intermediate group, and 84.9 percent in the higher group. That figure pools stages I to III. It is not stage III alone, and it is not stage IV (PMID 42449506).

RAPIDO enrolled 912 eligible adults with high-risk locally advanced rectal cancer on MRI: at least one of cT4a or cT4b, extramural vascular invasion, cN2, a threatened mesorectal fascia, or enlarged lateral nodes. At 3 years, the cumulative probability of disease-related treatment failure was 23.7 percent after short-course radiotherapy, chemotherapy, and total mesorectal excision, versus 30.4 percent with standard care. The hazard ratio was 0.75, interval 0.60 to 0.95. Grade 3 or higher diarrhea during preoperative treatment was 18 percent versus 9 percent, and treatment-related deaths occurred in both groups (PMID 33301740).

PRODIGE 23 randomized 461 people with cT3 or cT4 disease and no distant spread. Three-year disease-free survival was 76 percent with induction fluorouracil, leucovorin, irinotecan, and oxaliplatin before chemoradiotherapy, versus 69 percent with standard care. The intervals were 69 to 81 versus 62 to 74 (PMID 33862000).

2. A clinical complete response is not a finish line at year 4

A 2026 review reported pathologic complete response after total neoadjuvant therapy near 25 to 30 percent in locally advanced rectal cancer. In the international database of people selected for watch-and-wait, 5-year overall survival was about 85 percent and cancer-specific survival about 94 percent. Clinical complete response disagreed with pathologic response by 10 to 25 percent, and local regrowth was about 25 percent (PMID 42137461).

A meta-analysis of 6 studies and 597 people found that negative circulating tumor DNA after total neoadjuvant therapy was associated with a higher chance of clinical complete response, odds ratio 8.01, with a wide interval from 1.43 to 44.90. The association with a sustained response was not significant. A negative result did not show that no tumor remained at the primary site (PMID 42832577).

3. Morale is studied as one factor. It is not a 50-point survival shift

A psychoneuroimmunology review describes chronic stress in relation to CD8 T-cell and natural-killer surveillance, through the hypothalamic-pituitary-adrenal axis and sympathetic activation, and through beta-adrenergic signaling after catecholamines. The authors also describe limits of the methods, genetic differences, and behaviors such as smoking and inactivity. The paper does not report that lowering stress moves survival from the 30s to the 90s, and it does not offer morale in place of surgery, chemotherapy, or radiation (PMID 42753839).

A second person’s cancers in other organs have their own follow-up. That account is not evidence that one mechanism produces the same percentage.

4. The surveillance schedule belongs to the treating team

In 2013, ASCO endorsed a Cancer Care Ontario approach: history, examination, and CEA every 3 to 6 months for 5 years, with higher-risk people toward the more frequent end. Chest and abdominal CT is yearly for about 3 years in most cases. PET is not used for surveillance outside a trial. Colonoscopy is done 1 year after surgery, then about every 5 years depending on findings. If no colonoscopy was done before diagnosis, it is done after adjuvant therapy and before 1 year. A healthy weight and an active life are the secondary-prevention items. If severe comorbidity means further surgery or systemic therapy would not be offered, the surveillance tests themselves are not recommended (PMID 24220554).

That 2013 frame is adapted to the stage, the scans, and the operation. The page on CEA after stage 3–4 colorectal cancer explains why a normal CEA does not replace imaging.

5. Each number belongs to a different group

This table keeps a quoted percentage, a registry, and trials in separate rows. A number is not carried across rows as one person’s odds.

6. Food and structured exercise are a different size of effect

Among 1,011 people with stage III colon cancer, unprocessed red meat and processed meat after diagnosis were not associated with recurrence or death. Comparing the highest quartile with the lowest, the hazard ratio for processed meat and recurrence or death was 1.05, interval 0.75 to 1.47 (PMID 35191970).

CUP Global reviewed 5 trials and 35 cohort studies, more than 30,000 cases, and graded post-diagnosis diet evidence as limited. Plant-leaning patterns, whole grains, and coffee had limited-suggestive inverse associations with all-cause mortality. Sugary drinks had a limited-suggestive association in the other direction. The other specific exposures were not firm enough for an instruction (PMID 38692645).

CHALLENGE randomized 889 people with colon cancer to a 3-year structured exercise program after adjuvant chemotherapy, or to health education. Five-year disease-free survival was 80.3 versus 73.9 percent, a difference of 6.4 points, interval 0.6 to 12.2. Eight-year overall survival was 90.3 versus 83.2 percent. Musculoskeletal events were more common with exercise, 18.5 versus 11.5 percent. This was not rectal cancer, and it is not an unsupervised order to walk 30 minutes (PMID 40450658).

Symptoms that need a clinician

• Severe abdominal pain, vomiting, and no stool or gas need emergency care. That cluster can be a bowel obstruction.
• Heavy bleeding, collapse, or severe pain with fever needs same-day or emergency care.
• Unintended weight loss, a change from the person’s own bowel pattern, or a new deep ache should be told to the oncology team. A fast change does not wait for the next routine date, and it is not a home conclusion that the cancer has returned.
• Sudden chest pain, one-sided weakness, or trouble speaking needs emergency care.
• Hearing a higher percentage is not a reason to skip scheduled tests. If comorbidity means further cancer treatment would not be offered, whether to keep doing surveillance tests is the clinician’s decision.

Questions people ask

Can a quoted change from 30–40 percent to 80–90 percent be used for someone else?

No. One conversation is not a group survival rate. In a Dutch registry of stage I to III rectal cancer, 5-year relative survival was about 79.5 to 84.9 percent across socioeconomic groups. That figure is not stage IV, and it was not produced by a change in morale.

Do lymph-node involvement and distant organ spread share one survival figure?

They are different groups. RAPIDO enrolled high-risk locally advanced rectal cancer on MRI, including cT4, cN2, a threatened mesorectal fascia, or enlarged lateral nodes. PRODIGE 23 enrolled cT3 or cT4 disease without distant spread. A post that writes stage 3 and stage 4 together does not show which group a person is in.

Can morale move natural killer cells enough to lift survival from 30 percent to 90 percent?

A psychoneuroimmunology review describes chronic stress, the hypothalamic-pituitary-adrenal axis, sympathetic signaling, natural killer cells, and CD8 T cells, and it states the methodological limits. That paper did not measure a 50-point survival shift, and it does not replace chemotherapy, radiation, or surgery.

Does a clinical complete response mean the disease is finished by year 4?

No. A 2026 review put pathologic complete response after total neoadjuvant therapy near 25 to 30 percent. In a selected watch-and-wait database, 5-year overall survival was about 85 percent, local regrowth was about 25 percent, and clinical assessment disagreed with pathologic response by 10 to 25 percent.

What follow-up did ASCO endorse?

The 2013 ASCO endorsement describes history, examination, and CEA every 3 to 6 months for 5 years, chest and abdominal CT yearly for about 3 years in most people, and colonoscopy at 1 year then about every 5 years depending on findings. PET is not routine surveillance. The treating team still adapts the plan. A normal CEA is discussed further on the colorectal surveillance page.

Which symptoms need urgent care?

Severe pain with vomiting and no stool or gas needs emergency care because it can be a bowel obstruction. Heavy bleeding or collapse does too. Unintended weight loss should be told to the oncology team and is not a home conclusion that the cancer has returned. Chest pain or one-sided weakness needs emergency care.

Mechanism, as assembled by the author

Asst. Prof. Dr. Norawit Raatpiboon assembles the papers below as follows. Rectal-cancer survival is reported by stage and by trial, apart from a percentage one person remembers from a clinic visit. Stages I to III in one registry had 5-year relative survival in the low-to-mid 80 percent range. A high-risk trial still had disease-related treatment failure in about one in four people at 3 years in the stronger arm. People selected because they appeared to have a clinical complete response still had local regrowth in about one in four. Stress has been studied next to immune cells, without a measured 50-point survival shift. Diet after diagnosis remains limited evidence. A structured exercise program in colon cancer moved disease-free survival by about 6 points, not 50.

Sources

• PMID 42449506 5-year relative survival for stage I–III rectal cancer in the Netherlands
• PMID 33301740 RAPIDO, 3-year disease-related treatment failure
• PMID 33862000 PRODIGE 23, 3-year disease-free survival
• PMID 42137461 watch-and-wait, local regrowth, and survival in a selected group
• PMID 42832577 circulating tumor DNA and clinical complete response
• PMID 42753839 stress, natural killer cells, and the limits of that evidence
• PMID 24220554 2013 ASCO endorsement of colorectal surveillance
• PMID 35191970 red and processed meat after stage III colon cancer
• PMID 38692645 post-diagnosis diet, limited evidence
• PMID 40450658 structured exercise after colon-cancer chemotherapy

Medical disclaimer

This page is general education. It is not one person’s pathology or scan, and it is not an order to start, stop, or change chemotherapy, radiation, or surgery. Bowel obstruction, heavy bleeding, collapse, chest pain, or one-sided weakness needs local emergency services.